医学分子生物学杂志 ›› 2025, Vol. 22 ›› Issue (4): 325-331.doi: 10.3870/j.issn.1672-8009.2025.04.004

• 论著 • 上一篇    下一篇

MCL1 调控 GSK3β / Wnt / β-catenin 信号轴促进急性 T 淋巴细胞白血病细胞对维奈克拉耐药的机制研究 #br#

  

  1. 新疆医科大学第一附属医院血液病中心, 新疆维吾尔自治区血液病研究所 乌鲁木齐市, 830054
  • 出版日期:2025-07-31 发布日期:2025-07-18
  • 基金资助:
    新疆维吾尔自治区自然科学基金 (No. 2022D01C754)

MCL1 Promotes Drug Resistance of Acute T Lymphoblastic Leukemia Cells to Venetoclax by Regulating GSK3β/ Wnt / β-Catenin Axis #br#

  1. Xinjiang Uygur Autonomous Region Institute of Hematology, Hematology Center of the First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China
  • Online:2025-07-31 Published:2025-07-18

摘要: 目的 探究髓样细胞白血病因子 1 (myeloid cell leukemia factor 1, MCL1) 促进急性 T 淋巴细胞白血病 (acute T lymphocytic leukemia, T-ALL) 细胞对维奈克拉耐药的分子机制。 方法 培养 T-ALL 亲本细胞系 Jurkat 和 T-ALL 维奈克拉耐药细胞系 Jurkat / VEN, 将靶向 MCL1 的小干扰 RNA (si-MCL1) 和阴性对照 (si-NC) 转染至 Jurkat / VEN 细胞, RT-qPCR 和蛋白质印迹法检测转染后细胞中 MCL1 表达以验证转染效果, 蛋白质印迹法检测转染后细胞中糖原合成酶激酶 3β ( glycogen synthase kinase-3β, GSK3β)、 磷酸化 GSK3β (p-GSK3β)、 β-连环蛋白 ( β-catenin)、 骨髓细胞瘤病毒癌基因 ( c-Myc)、 细胞周期蛋白 D1 (cyclin D1) 表达。 Jurkat / VEN 细胞分为对照组、 si-NC 组、 si-MCL1 组、 si-MCL1 + CHIR-99021 组。 CCK-8法、 克隆形成实验和流式细胞术分别检测不同浓度 (0、 100、 200、 300、 400、 500 nmol / L) 维奈克拉处理下各组 Jurkat / VEN 细胞存活率、 形成的克隆数目及细胞凋亡率。 结果 与 Jurkat 细胞比较, Jurkat / VEN细胞中 MCL1 蛋白表达增加 (P< 0. 05), GSK3β 蛋白表达减少 ( P< 0. 05), p-GSK3β 及 β-catenin、 c-Myc、Cyclin D1 蛋白表达增加 (P< 0. 05); 细胞转染后, 与对照组、 si-NC 组比较, si-MCL1 组 Jurkat / VEN 细胞中 MCL1 mRNA 及蛋白表达减少 ( P < 0. 05), GSK3β 蛋白表达增加 ( P < 0. 05), p-GSK3β、 β-catenin、 cMyc、 Cyclin D1 蛋白表达减少 (P< 0. 05)。 与对照组、 si-NC 组比较, si-MCL1 组 Jurkat / VEN 细胞在各浓度维奈克拉作用下的存活率和 IC50值降低 ( P< 0. 05), 克隆数目减少 ( P< 0. 05), 凋亡率升高 ( P< 0. 05);与 si-MCL1 组比较, si-MCL1 + CHIR-99021 组 Jurkat / VEN 细胞在各浓度维奈克拉作用下的存活率和 IC50 值升高 (P< 0. 05), 克隆数目增加 ( P< 0. 05), 凋亡率降低 ( P< 0. 05)。 结论 干扰 MCL1 表达可降低Jurkat / VEN 细胞对维奈克拉的耐药性, 这可能是通过阻断 GSK-3β / Wnt / β-catenin 信号轴实现的。

关键词:

急性 T 淋巴细胞白血病, 髓样细胞白血病因子 1, 维奈克拉, 耐药

Abstract: Objective To investigate the molecular mechanism by which myeloid cell leukemiafactor 1 ( MCL1) promotes the resistance of acute T lymphoblastic leukemia ( T-ALL) cells tovenetoclax. Methods T-ALL parental cell line Jurkat and T-ALL venetoclax-resistant cell line Jurkat / VEN were cultured, and small interfering RNA targeting MCL1 (si-MCL1) and negative control (si-NC) were transfected into Jurkat / VEN cells. RT-qPCR and Western blotting were used to detect the expression level of MCL1 in transfected cells to verify the transfection effect. The expression levels of GSK3β, phosphorylated GSK3β ( p-GSK3β), β-catenin, c-Myc, and cyclin D1 were detected by Western blotting. Jurkat / VEN cells were divided into 4 groups: control group, siNC group, si-MCL1 group, si-MCL1 + CHIR-99021 group. The CCK-8 method was used to detect the survival rate of Jurkat / VEN cells in each group under different concentrations (0, 100, 200, 300, 400, 500 nmol / L) of venetoclax, the colony formation assay was used to detect the numberof colonies formed in each group, and the flow cytometry was used to detect the apoptosisrate. Results Compared with those in the Jurkat cells, the protein expression level of MCL1 in theJurkat / VEN cells was increased (P < 0. 05), the expression level of GSK3β was decreased (P <0. 05), and the expression levels of p-GSK3β, β-catenin, c-Myc and Cyclin D1 were increased(P < 0. 05) . Compared with those in the control group and si-NC group, the mRNA and proteinexpression levels of MCL1 were decreased in the si-MCL1 group (P < 0. 05), the expression levelof GSK3β was increased (P < 0. 05), and the expression levels of p-GSK3β, β-catenin, c-Mycand Cyclin D1 proteins were decreased (P< 0. 05) . Compared with those in the control group andsi-NC group, the survival rate after venetoclax treatment and the value of IC50 were decreased in thesi-MCL1 group (P< 0. 05), the number of colonies was decreased (P< 0. 05), and the apoptosisrate was increased (P< 0. 05) . Compared with those in the si-MCL1 group, the survival rate aftervenetoclax treatment and the value of IC50 were increased in the si-MCL1 + CHIR-99021 group (P<0. 05), the number of colonies was increased (P < 0. 05), and the apoptosis rate was decreased(P< 0. 05) . Conclusion Interference in MCL1 expression can reduce the drug resistance ofJurkat / VEN cells to venetoclax, which may be achieved by blocking the GSK-3β / Wnt / β-cateninsignaling axis.

Key words: acute T lymphocytic leukemia, myeloid cell leukemia factor 1, venetoclax, drug resistance

中图分类号: